Crescent Biopharma (CBIO) Operating Leases (2019 - 2026)

Crescent Biopharma (CBIO) has 7 years of Operating Leases data on file, last reported at $1.1 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $1.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (changed N/A YoY), and the FY2025 annual result was $1.2 million, changed N/A from the prior year.
• Operating Leases eased to $1.1 million in Q1 2026 per CBIO's latest filing, from $1.2 million in the prior quarter.
• Over five years, Operating Leases peaked at $1.6 million in Q2 2025 and troughed at $66844.0 in Q4 2023.
• A 4-year average of $714694.3 and a median of $550280.5 in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2023: Operating Leases tumbled 91.9% in 2022, then surged 174.16% in 2023.
• A 4-year view of Operating Leases shows it stood at $95613.0 in 2022, then plunged by 30.09% to $66844.0 in 2023, then jumped by 1708.69% to $1.2 million in 2025, then slipped by 9.84% to $1.1 million in 2026.
• Business Quant data shows CBIO's Operating Leases at $1.1 million in Q1 2026, $1.2 million in Q4 2025, and $1.3 million in Q3 2025.